Last updated: April 24, 2026
Who Supplies Mitomycin (Drug Substance and Finished Dosage Forms)?
Mitomycin (mitomycin) is supplied globally through a mix of originator legacy manufacturers, generic API producers, and finished-dose makers. The market breaks into two procurement tracks: (1) mitomycin drug substance (API) and (2) packaged mitomycin drug products (injection/lyophilized vials in many jurisdictions).
What follows is a procurement-ready supplier map based on major, repeatedly listed manufacturers tied to mitomycin API and commercial injection products.
Which Companies Supply Mitomycin Drug Substance (API)?
Mitomycin API is typically manufactured under GMP and distributed for formulation into injectable products. Commonly encountered API supply sources include:
| Supplier (Company) |
Supply role in market |
Notes on typical procurement use |
| Kyowa Hakko Bio / Kyowa Hakko Kirin group entities |
API and/or commercial drug supply |
Historical origin and ongoing supply presence across markets where mitomycin-based regimens are used. |
| Lupin |
API and/or finished supply |
Large generics footprint; common distributor for oncology injectables and related oncology inputs. |
| Mylan (legacy and successors) |
Finished-dose and/or supply chain for generic oncology |
Often appears in market history for injectable oncology products. |
| Sandoz |
Finished-dose and/or supply chain presence |
Major generic injectable platform with mitomycin legacy listings in multiple countries. |
| Accord Healthcare |
Finished-dose |
Frequent oncology injectable supplier in Europe and other regulated markets. |
| Teva |
Finished-dose |
Large-scale generic sterile portfolio; mitomycin appears in historical and regional catalogs. |
| Sun Pharmaceutical Industries |
Finished-dose and/or API supply chain |
Oncology injectable scale; mitomycin appears in multiple regional offerings. |
| Hospira/Pfizer (legacy branded portfolios) |
Legacy supply and/or market presence |
Mitomycin injection has been marketed by major legacy players in some jurisdictions. |
Procurement implication: For API sourcing, buyers usually qualify multiple suppliers because mitomycin supply is constrained by sterile manufacturing capacity and oncology portfolio volatility. For drug product sourcing, the key variable is regional MAH (marketing authorization holder) and sterile fill-finish network rather than API manufacturer identity.
Which Companies Supply Mitomycin Finished Drug Products (Injection/Vials)?
Mitomycin is most commonly sold as injectable (often as a sterile powder for reconstitution or lyophilized vial depending on market). Finished-dose suppliers frequently include the following globally visible generic and established oncology players:
EU/UK-style generic suppliers (finished product makers)
- Accord Healthcare
- Sandoz
- Hospira (legacy in some markets)
- Teva
- Sun Pharmaceutical Industries
Non-EU/regional generic oncology platforms (finished product makers)
- Lupin
- Mylan (legacy and successors)
- Cipla (regional presence)
- Dr. Reddy’s Laboratories (regional presence)
How to map “supplier” in practice
In finished-dose procurement, the relevant contracting party is often:
- MAH / Marketing Authorization Holder (regional legal entity), and
- Manufacturer on the label (sterile manufacturer and/or packager),
not always the same company as the API producer.
What Dosage-Form and Label Supply Chains Look Like for Mitomycin
Mitomycin is typically managed in distribution as sterile oncology products. Common packaging patterns by market include:
- Single-dose vials (often powder/lyophilized with reconstitution instructions)
- Sterile injection presentations that require refrigerated or controlled storage in some jurisdictions
- Oncology distribution with cold-chain or special handling depending on local regulatory label requirements
Procurement implication: Supplier selection must be aligned to the buyer’s:
- route to market (hospital tender vs distributor),
- required pack size and strength (varies by jurisdiction),
- and sterile manufacturing certification history.
How Do You Shortlist Suppliers for Mitomycin in a Tender or R&D Context?
A practical supplier shortlisting rubric for mitomycin procurement typically weights:
- Regulatory status in the target market
- Product authorization is the gate.
- Sterile manufacturing and QC documentation
- Sterility assurance, endotoxin controls, and reconstitution stability are decisive.
- Continuity of supply
- Oncology products experience tender volatility.
- Compatibility with your formulation plan
- If sourcing API for in-house or CDMO formulation, buyers verify impurity profile and particle specs as controlled by the supplier’s CoA ranges.
Key Takeaways
- Mitomycin supply splits into API manufacturers and finished-dose injection makers, and these roles often sit in different companies.
- Major generic oncology platforms that commonly appear as suppliers include Accord Healthcare, Sandoz, Teva, Sun Pharma, Lupin, and legacy Hospira/Pfizer, depending on jurisdiction.
- For procurement, buyers should prioritize MAH and label-identified sterile manufacturer for finished products, and GMP-qualified API production for API sourcing.
FAQs
1) Is mitomycin supplied primarily as an API or a finished injection?
It is primarily purchased as finished injectable vials for clinical use, while API sourcing is common for manufacturing partnerships, compounding workflows where permitted, or CDMO formulation.
2) Which type of supplier matters most for hospital tenders?
For hospital and health-system procurement, the decisive factor is the finished-dose legal authorization (MAH) and the sterile manufacturer on the label, not only the API producer.
3) Are mitomycin suppliers consistent across all countries?
No. The same strength and presentation can have different MAHs, and supply can shift by region due to distribution contracts and regulatory approvals.
4) Can you treat “API manufacturer” and “finished-dose maker” as the same supplier?
Often they are different. Many finished-dose products source API from a different entity than the company that produces and packs the sterile vials.
5) What is the most common dosage form encountered in the market?
Injectable vials, frequently as powder/lyophilized for reconstitution or sterile injection presentations, depending on country labeling.
References
- U.S. Food and Drug Administration. “Drug Products (Orange Book): Mitomycin.” FDA, https://www.accessdata.fda.gov/scripts/cder/daf/.
- European Medicines Agency (EMA). “European public assessment reports for mitomycin products.” EMA, https://www.ema.europa.eu/.
- World Health Organization (WHO). “Mitomycin (substance information in WHO references and pharmacopoeial contexts).” WHO, https://www.who.int/.
